Overview

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and whose first line of fluoropyrimidine- and platinumcontaining treatment has failed. The co-primary endpoints are the following: - Six months survival rate - Quality of life at 4 months as assessed by the following three target dimensions of the EORTC QLQ-ELD14 questionnaire: mobility, illness burden and worries about the future

Phase:

Phase 2

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Collaborator:

Eli Lilly and Company

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Paclitaxel
Ramucirumab